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Asthma  is  an  obstructive  airway  disease  that   
affects an unusually large segment of the popula-
tion and results in significant morbidity, and at 
times mortality. It is well appreciated that pre-
disposition to asthma is genetically determined, 
whereas its clinical expression is controlled by 
environmental factors (Gern et al., 1999). Genes 
of  the  IL-4–IL-13–IL-4R  cytokine  pathway 
have been identified as leading candidates in 
conferring susceptibility to asthma (Ober and 
Hoffjan, 2006). These functionally overlapping 
cytokines are key effectors of Th2-dependent 
responses, including stimulation of IgE synthe-
sis, modulation of lymphocyte and antigen-
  presenting cell function, and induction of allergic 
inflammation. In the allergen-exposed airway, 
this inflammatory response involves recruitment 
of eosinophils, mucin hypersecretion, genera-
tion of airway hyperresponsiveness (AHR), and, 
eventually, airway remodeling, characterized by 
subepithelial fibrosis, neovascularization, and other 
permanent alterations in airway microanatomy 
(Elias et al., 1999).
IL-4 and IL-13 share a common receptor 
component, the IL-4R chain, that pairs with 
distinct subunits (Nelms et al., 1999; Hershey, 
2003; Chatila, 2004). IL-4R pairs with the 
common c chain to form a type I IL-4R com-
plex that is found predominantly in hematopoi-
etic cells and is exclusive for IL-4. IL-4R also 
pairs with the IL-13R1 subunit to form a type 
II IL-4R that binds both IL-4 and IL-13. The 
type II receptor is expressed on both hemato-
poietic and nonhematopoietic cells such as   
airway epithelium. IL-4 and IL-13 activate re-
ceptor-associated Janus kinases, which initiate 
several intracellular signaling cascades by phos-
phorylating specific tyrosine (Y) residues in the 
cytoplasmic domain of IL-4R (Nelms et al., 
1999; Hershey, 2003; Chatila, 2004). Phos-
phorylation of Y575, Y603, and Y633 of hu-
man IL-4R mobilizes the transcription factor 
STAT6,  which  induces  IL-4–  and  IL-13–
  responsive genes. Additional cell growth and 
regulatory functions are served by Y497, which 
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Polymorphisms in the interleukin-4 receptor  chain (IL-4R) have been linked to asthma 
incidence and severity, but a causal relationship has remained uncertain. In particular, a 
glutamine to arginine substitution at position 576 (Q576R) of IL-4R has been associated 
with severe asthma, especially in African Americans. We show that mice carrying the Q576R 
polymorphism exhibited intense allergen-induced airway inflammation and remodeling. The 
Q576R polymorphism did not affect proximal signal transducer and activator of transcription 
(STAT) 6 activation, but synergized with STAT6 in a gene target– and tissue-specific manner 
to mediate heightened expression of a subset of IL-4– and IL-13–responsive genes involved 
in allergic inflammation. Our findings indicate that the Q576R polymorphism directly pro-
motes asthma in carrier populations by selectively augmenting IL-4R–dependent signaling.
© 2009 Tachdjian et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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(Fig. S1 B). Matings of IL-4R heterozygotes (Hets) resulted 
in generation of R576 homozygous mutant mice in numbers 
consistent with Mendelian inheritance. Homozygous mutant 
mice of both sexes were phenotypically indistinguishable from 
their WT and Het littermates. The transmission and integrity 
of the mutant allele was verified by several methods, including 
Southern blot analysis, allele-specific PCR amplification, and 
direct sequencing of genomic DNA (Fig. S1, B–D; and not 
depicted). Expression of mutant receptor protein was verified 
by flow cytometry to be closely matched to WT controls   
(Fig. S1 E). Analysis revealed the T and B lymphocytes of the 
IL-4R R576 mutant mice to be normal in number and phe-
notype (unpublished data).
The R576 allele promotes antigen-induced allergic  
airway inflammation and remodeling
The functional consequences of the R576 mutation were 
analyzed in antigen-driven mouse models of allergic airway 
inflammation. In an acute model of allergic airway inflamma-
tion, C.129.Il4raR576/R576 and C.129.Il4raQ576/Q576 mice were 
i.p. sensitized and boosted with OVA in alum, and challenged 
at 4 wk after sensitization with inhaled OVA for three con-
secutive days. Control mice were immunized and boosted 
with PBS/alum and challenged with inhaled OVA. Exami-
nation of lung tissue of WT and mutant mice stained with 
hematoxylin and eosin (H&E) revealed patchy peribronchial 
inflammatory infiltrates, composed primarily of eosinophils 
and  lymphocytes,  that  were  substantially  more  prominent   
in OVA-sensitized and -challenged C.129.Il4raR576/R576 mice   
as compared with C.129.Il4raQ576/Q576 controls (Fig. 1 A).   
In contrast, sham-immunized mice exposed to aerosolized 
OVA showed normal lung histology (unpublished data). 
Significantly, OVA-challenged C.129.Il4raR576/R576 mutants 
exhibited markedly increased peribronchial and perivascu-
lar inflammation and increased numbers of goblet cells com-
pared with C.129.Il4raQ576/Q576 controls (Fig. 1, B and C; 
Grünig et al., 1998; Wills-Karp et al., 1998; Dabbagh et al., 
1999; Kuperman et al., 2002). Analysis of bronchoalveolar 
lavage (BAL) fluid of OVA-sensitized and -challenged mice 
revealed that C.129.Il4raR576/R576 mice exhibited increased 
accumulation of eosinophils in the airways as compared with 
similarly treated controls (Fig. 1 D). These results indicated 
that the R576 substitution caused an increase in the airway 
inflammatory response to allergen.
We next examined the impact of the R576 mutation on 
airway inflammation and remodeling in chronic OVA-driven 
allergic airway inflammation (Wegmann et al., 2005). This 
model better reflects some of the physiological changes 
associated with chronic asthma, including subepithelial 
fibrosis.  Accordingly,  C.129.Il4raR576/R576  and  control 
C.129.Il4raQ576/Q576 mice were sensitized and boosted with 
OVA in alum, and starting at week 4 after sensitization they 
were challenged with OVA by inhalation twice daily for an 
additional 8 wk (Wegmann et al., 2005). Histological analy-
sis revealed that the C.129.Il4raR576/R576 mice exhibited 
increased perivascular inflammation and tissue eosinophilia 
activates phosphatidylinositol 3 (PI3)–kinase and mitogen-
  activated protein kinase (MAPK) pathways, and by an immuno-
receptor tyrosine-based inhibitory motif (ITIM) at Y713 that   
activates phosphotyrosine and inositol phosphatases.
An essential role for IL-4R signaling in asthma patho-
genesis has been established (Chatila, 2004). Increased expres-
sion of IL-13 and, to a lesser extent, IL-4 in mouse airways 
reproduces many of the pathophysiological changes that are 
typical of asthma (Elias et al., 1999). Blockade of IL-13 or de-
letion of IL-4R or STAT6 genes renders mice resistant to 
the induction of experimental allergic asthma (Grünig et al., 
1998; Wills-Karp et al., 1998). IL-4R chain expression in 
resident airway tissues is required for development of allergic 
airway inflammation upon antigen exposure. Induction of 
AHR, goblet cell metaplasia, and mucin overproduction have 
been found to be dependent on IL-4R signaling in airway 
epithelial cells (Kuperman et al., 2002). Furthermore, coding 
genetic polymorphisms in the human IL-4R chain gene 
have been implicated in susceptibility to both atopy and 
asthma (Hershey et al., 1997; Ober et al., 2000; Howard et al., 
2002). Of particular interest is the Q576R polymorphism that 
is associated with asthma susceptibility in outbred populations, 
especially severe asthma (Hershey et al., 1997; Rosa-Rosa   
et al., 1999; Ober et al., 2000; Sandford et al., 2000; Wenzel 
et al., 2007). The Q576R polymorphism has also been linked 
to  severe  respiratory  syncytial  virus–induced  bronchiolitis 
(Hoebee et al., 2003), rapid decline in lung function in smok-
ers (He et al., 2003), and heightened allergen sensitization in 
the context of maternal smoking (Liu et al., 2004). Of inter-
est,  this  allele  is  overrepresented  in  the  African-American 
population (70% allele frequency in African Americans vs. 
20% in Caucasians, giving rise to 50 and 4% homozygosity, 
respectively; Caggana et al., 1999; Ober et al., 2000; Wu   
et al., 2001; Akinbami and Schoendorf, 2002; Mannino et al., 
2002). In concert with increased frequency of the Q576R 
polymorphism, African Americans suffer from heightened 
asthma prevalence and severity. To address the role of the 
Q576R polymorphism in allergic airway inflammation, we 
have developed a mouse model in which the Q576 residue, 
which is conserved in mice, is changed to R576.
RESULTS
Generation of IL-4RR576 mutant mice by targeted  
knock-in mutagenesis
To elucidate the impact of the human Q576R polymorphism 
on IL-4R function, we adopted a genetic approach that took 
advantage of the conservation of the Q576 motif (peptide se-
quence 574-GYQEFG-579) in mouse and human to substi-
tute the equivalent glutamine residue of the mouse receptor 
(also Q576) with arginine. A targeting construct was designed 
to replace exon 12 of Il4ra of embryonic stem (ES) cells with 
another  bearing  AG→GA  substitutions  at  the  second  and 
third positions of the Q576 codon that changed the codon 
specificity to R576 (Fig. S1 A; Wrighton et al., 1992). Suc-
cessfully targeted ES clones were used to derive mouse male 
chimera that transmitted the R576 mutation into the germline JEM VOL. 206, September 28, 2009 
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as compared with control mice (Fig. 2, A–E, arrows in   
B and D). Sirius red staining revealed markedly increased 
subepithelial  collagen  deposition  in  the  mutant  mice  as 
compared with controls (Fig. 2, F–J). These findings indi-
cated that the R576 mutation exacerbated chronic sequelae 
of airway inflammation, such as airway remodeling, that are 
key determinants of disease morbidity in asthma.
The R576 allele promotes IL-13–induced allergic  
airway inflammation
Many aspects of antigen-induced allergic airway inflamma-
tion, including AHR, eosinophilic infiltration, goblet cell 
metaplasia, and tissue remodeling, can be induced by the 
direct action of IL-13 on resident airway tissue independent 
of the adaptive immune response. To determine whether 
Figure 1.  The Q576R substitution promotes acute antigen-
induced allergic airway inflammation. OVA-sensitized C.129.Il4raQ576/Q576 
(Q576) and C.129.Il4raR576/R576 (R576) mice (n = 13 and 11, respectively) 
were challenged intranasally with OVA on three consecutive days and 
analyzed. (A) Lung histology (PAS staining). (B) Semiquantitative analysis 
of the severity of peribronchial inflammation represented by the mean of 
the inflammation scores, as described in Materials and methods. (C) Enu-
meration of PAS-positive goblet cells in the airways. (D) BAL fluid analysis 
for inflammatory cells. Values represent means ± SEM derived from two 
independent experiments. *, P < 0.05; **, P < 0.01. Bar, 200 µm.
Figure 2.  The Q576R substitution promotes airway inflammation 
and remodeling after chronic allergen challenge. (A–E) Sham- (PBS) 
and OVA-sensitized C.129.Il4raQ576/Q576 and C.129.Il4raR576/R576 mice (n = 
15–20 per group) were challenged intranasally with PBS and OVA, respec-
tively, twice weekly for 12 wk. Airway inflammation was analyzed by his-
tology (H&E staining; A–D), and inflammatory cells in the lung 
parenchyma were enumerated (E). Arrows in B and D represent areas of 
perivascular infiltration. (F–J) Detection (F–I) and quantitation (J) of sub-
epithelial collagen deposition by Sirius red staining. Values represent 
means ± SEM of results from 8–10 mice derived from two independent 
experiments. HPF, high power field. *, P < 0.05; **, P < 0.01. Bars, 100 µm.2194 IL4RA ALLELES IN ASTHMA PATHOGENESIS | Tachdjian et al.
eosinophilia as compared with the B6.Il4raQ576/Q576/IL-13tg 
single-transgenic mice, and this difference was further ampli-
fied upon doxycycline induction of IL-13 (Fig. 4 A). Al-
though the single- and double-transgenic mice exhibited 
equivalent  percentages  of  goblet  cells  at  baseline,  the 
B6.129Il4raR576/R576/IL-13tg double-transgenic mice were 
more responsive to doxycycline treatment. While the per-
centage of goblet cells doubled upon doxycycline treatment 
of IL-13tg single-transgenic mice, it nearly quadrupled in 
the  similarly  treated  B6.129Il4raR576/R576/IL-13tg  double-
transgenic mice (Fig. 4 B). The enhanced airway eosino-
philia  in  doxycycline-treated  B6.129Il4raR576/R576/IL-13tg 
mice was associated with increased detection by real-time 
PCR analysis of mRNA encoding the eosinophil chemotac-
tic factor Ccl11 (eotaxin; Fig. 4 C). In contrast, transcripts of 
other chemokines such as Ccl2 were not significantly affected 
(Fig. 4 D). The capacity of the R576 mutation to up-regulate 
IL-13–induced Ccl11 expression in the airways was mir-
rored in studies on primary cell cultures of several lineages 
involved in allergic airway inflammation. Both IL-4– and 
IL-13–induced Ccl11 expression was increased in bone mar-
row–derived macrophages (BMDMs) and lung fibroblasts 
derived from R576 mutant mice as compared with WT 
controls (Fig. 4 E). Collectively, these results established that 
the  R576  substitution  heightened  IL-13–induced  allergic 
airway inflammation and tissue eosinophilia irrespective of 
the genetic background of the mice tested.
the R576 mutation could augment IL-13–induced airway 
inflammation, C.129.Il4raR576/R576 and WT BALB/c con-
trol mice were subjected to daily instillations of recombi-
nant IL-13 or vehicle alone (BSA) for three consecutive 
days and compared for the magnitude of their responses. 
For both genotypes, the IL-13–challenged mice developed 
an allergic inflammatory response characterized by AHR to 
methacholine,  eosinophilic  infiltration,  and  goblet  cell 
hyperplasia. (Fig. 3, A–D). However, for each of these param-
eters the C.129.Il4raR576/R576 mice exhibited an enhanced 
response as compared with WT BALB/c control mice, indi-
cating that the R576 substitution augmented the IL-13–induced 
airway inflammation.
These results were validated in a second IL-13–dependent 
allergic airway inflammatory model that used a doxycycline-
responsive IL-13 transgene (tg) driven by the Clara cell–
  specific promoter CC10 and maintained on a C57BL/6 
background. Double-transgenic B6.129Il4raR576/R576/IL-13tg   
mice  were  derived  and  compared  with  single-transgenic 
B6.Il4raQ576/Q576/IL-13tg mice for allergic airway inflamma-
tion both in the absence of and upon treatment with doxy-
cycline for a total of 7 d. Both sets of mice exhibited basal 
airway eosinophilia and goblet cell metaplasia as compared 
with their respective IL-13tg-negative controls, a reflection 
of the leaky nature of the IL-13tg (Fig. 4 A; Zheng et al., 
2000). Importantly however, the B6.129Il4raR576/R576/IL-13tg 
double-transgenic mice exhibited increased basal airway 
Figure 3.  The Q576R substitution promotes airway hyperreactivity, airway eosinophilia, and goblet cell metaplasia after IL-13 administra-
tion. (A) WT BALB/c mice (Q576; genotype Il4raQ576/Q576) and C.129.Il4raR576/R576 (R576) mutant mice (n = 14–15 mice per group) were tested for their 
enhanced pause (Penh) response, a proxy measure of AHR, to aerosolized methacholine at 96 h after three daily intranasal instillations of IL-13 or BSA (5 µg  
each). Group responses were analyzed by repeated measures ANOVA (P < 0.001, R576/IL-13 vs. Q576/IL-13 groups). (B) Eosinophil count in BAL fluid.  
(C) PAS staining of IL-13–treated lung tissue. Arrowheads represent PAS+ goblet cells. (D) Enumeration of PAS-positive goblet cells. Values represent  
means ± SEM derived from three to four independent experiments. **, P < 0.01; ***, P < 0.001. Bar, 100 µm.JEM VOL. 206, September 28, 2009 
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Expression profiling revealed that the induction by doxy-
cycline of IL-13tg expression resulted in the up-regulation of 
related sets of canonical IL-13–responsive genes in the B6.
Il4raQ576/Q576/IL-13tg and B6.129Il4raR576/R576/IL-13tg mice 
as compared with their respective control groups (Tables   
S1 and S2). Comparison of the gene sets up-regulated by the 
IL-13tg revealed several asthma-related genes that met a 
rather restrictive criterion for selection (a twofold change 
cutoff in expression) on the R576 but not the Q576 back-
ground (Tables S3 and S4). A more direct comparison of   
the magnitude of gene expression in doxycycline-treated 
B6.129Il4raR576/R576/IL-13tg  versus  B6.Il4raQ576/Q576/IL-13tg 
mice, done at a more inclusive 1.2-fold change cutoff, contin-
ued to reveal enhanced expression of several IL-13–responsive 
genes in the homozygous R576 allele group as compared 
with their Q576 counterparts (Fig. 5 A and Table S5). These 
included genes involved in airway inflammation and remod-
eling such as Retnlb (resistin-like ) and Alox15 (15 lipoxy-
genase; Chu et al., 2002; Mishra et al., 2007), goblet cell 
metaplasia (Clca3 and Clca1) (Nakanishi et al., 2001), mucin 
and mucin granule components (Muc5b and Gp2), regulators 
The R576 allele up-regulates a subset  
of IL-13–responsive genes
To determine potential mechanisms underlying the trophic 
effects of the R576 allele on airway inflammation and remod-
eling, we first compared the gene expression profile in the 
lungs of doxycycline-treated B6.129Il4raR576/R576/IL-13tg 
mice versus B6.129Il4raR576/R576 littermates that lacked the 
IL-13tg (n = 11 and 5, respectively). We similarly compared the 
gene expression profile in the lungs of doxycycline-treated 
B6.Il4raQ576/Q576/IL-13tg mice versus tg-negative littermates 
(n = 8 and 5, respectively). Lastly, we directly compared 
the  gene  expression  profiles  in  the  doxycycline-treated 
B6.129Il4raR576/R576/IL-13tg versus B6.Il4raQ576/Q576/IL-13tg 
mice. Experimentally, total RNA was isolated, and then 
amplified and hybridized on Affymetrix 430 2.0 chips. Only 
those gene probe comparisons that were statistically significant 
(P < 0.05) were considered valid. Results were also compared 
with other published gene expression profiles in IL-13 and 
allergen-induced allergic airway inflammation (Zimmermann 
et al., 2003, 2004, 2005; Kuperman et al., 2005; Follettie   
et al., 2006).
Figure 4.  The Q576R substitution promotes IL-13tg–induced airway eosinophilia and goblet cell metaplasia. (A and B) B6.Il4raQ576/Q576, 
B6.129Il4raR576/R576, B6.Il4raQ576/Q576/IL-13tg single-, and B6.129Il4raR576/R576/IL-13tg double-transgenic mice (n = 10–17 per group) were treated for 1 wk with 
doxycycline. The mice were then analyzed for BAL fluid eosinophilia (A) and goblet cell metaplasia by PAS staining (B). Horizontal bars in A represent means. 
(C and D) Real-time PCR analysis of Ccl11 (C) and Ccl2 (D) mRNA levels in total lung extracts of sham- and doxycycline-treated mice (n = 8–14 per group). 
(E) Real-time PCR analysis of Ccl11 expression in IL-4– and IL-13–treated BMDMs, lung fibroblasts, and airway epithelial cells (n = 4–14 per group). Values 
represent means ± SEM derived from 3–4 independent experiments (A–D) and 4–14 independent experiments (E). *, P < 0.05; **, P < 0.01; ***, P < 0.001.2196 IL4RA ALLELES IN ASTHMA PATHOGENESIS | Tachdjian et al.
vitro into Th1 or Th2 effector lymphocytes. C.129.Il4raR576/R576   
Th2 cells exhibited a significant increase in IL-4 produc-
tion as compared with C.129.Il4raQ576/Q576 Th2 cells. In con-
trast, production of the Th2 cytokines IL-5 and IL-13 was   
not  significantly  different  between  the  two  populations   
(Fig. 6 A). Similarly, there was no significant difference in 
IFN- production between Th1 cells of the respective geno-
type. These results indicated that the R576 substitution selec-
tively up-regulated IL-4 production by Th2 cells.
The impact of the Q576R polymorphism on humoral 
immunity was examined by measuring the total and anti-
gen-specific antibody responses after immunization with 
OVA mixed with alum adjuvant to promote Th2-type re-
sponses (Brewer et al., 1999), or with saline/alum as immu-
nization control. Fig. 6 B revealed that the C.129.Il4raR576/R576 
mice  exhibited  increased  total  serum  concentrations  of   
IgE after immunization with OVA/alum as compared with 
C.129.Il4raQ576/Q576 control mice. In contrast, IgG1 levels were 
unchanged (unpublished data). Significantly, OVA-specific 
antibody responses were also increased in the Q576R mutant 
mice as compared with controls (Fig. 6 B). The heightened 
IgE production in the Q576R mutant mice was associated 
with an increased capacity of the C.129.Il4raR576/R576 B cells 
to produce IgE but not IgG1 when stimulated in vitro 
with anti-CD40 mAb plus IL-4 (Fig. 6 C). Also, the R576 
of ion transport (Fxyd3 and Fxyd4) (Geering, 2006), protease 
and protease inhibitors (Adam8 and Timp4) (King et al., 2004), 
and epithelial barrier formation (Sprr2a; Zimmermann et al., 
2005; Segre, 2006). When normalized for gene expression 
in  the respective control groups, several IL-13–responsive 
genes persisted in being overexpressed in doxycycline-treated 
B6.129Il4raR576/R576/IL-13tg as compared with similarly treated 
B6.129Il4raQ576/Q576/IL-13tg mice, including Adra2a, Alox15, 
Clca3, Fxyd4, Gp2, Muc5b, and Sprr2a (Fig. 5 B). The results 
of the gene array studies were further validated by real-time 
PCR analysis, which confirmed the up-regulation by the 
R576 substitution of several IL-13–induced genes, including 
Alox15, Retnlb, and Sprr2a (Fig. 5 C). These results estab-
lished that the R576 substitution differentially up-regulated 
the transcription of a subset of IL-13–responsive genes, espe-
cially ones involved in mucus secretion and airway inflamma-
tion and remodeling.
The R576 mutation promotes IL-4 production by Th2 cells 
and IgE responses
To determine whether the R576 substitution influenced   
Th cell differentiation as a contributing factor in its promo-
tion of allergic airway inflammation, we compared cytokine 
production of T cells of C.129.Il4raR576/R576 and control 
C.129.Il4raQ576/Q576 mice that were induced to differentiate in 
Figure 5.  The R576 substitution heightens the expression of a subset of IL-13–induced genes in the airways. (A) Differential expression of a 
subset of IL-13–induced genes in doxycycline-treated (Dox) B6.129Il4raR576/R576/IL-13tg double-transgenic versus B6.Il4raQ576/Q576/IL-13tg single-trans-
genic mice (n = 11 and 8, respectively). Results depict mean fold change values scoring P < 0.05 by the Student’s unpaired two-tailed t test. (B) Selected 
results from A were normalized for gene expression levels in doxycycline-treated, IL-13tg–negative B6.129Il4raR576/R576, and B6.Il4raQ576/Q576 littermate 
controls, respectively (n = 5 for each control group). (C) Real-time PCR analysis of Alox15, Retnlb, and Sprr2a mRNA levels in total lung extracts of doxy-
cycline-treated and IL-13tg–negative and –positive Q576 and R576 mice (n = 4–11 per group). Values represent means ± SEM derived from two to four 
independent experiments. *, P < 0.05; and **, P < 0.01 for doxycycline-treated R576/IL-13tg versus Q576/IL-13tg groups.JEM VOL. 206, September 28, 2009 
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We also examined the impact of the R576 substitution 
on the induction in BMDMs of the STAT6-dependent genes 
arginase 1 (Arg1) and chitinase (Chi3l3) and of arginase enzymatic 
activity (Gordon, 2003; Munitz et al., 2008; Ramalingam et al., 
2008). Although the R576 substitution augmented Ccl11 
gene expression in BMDMs (Fig. 4), it did not influence the 
induction of Arg1 and Chi3l3 transcripts nor the expression 
of arginase enzymatic activity in BMDM cells treated with 
IL-4 or IL-13 (Fig. S2). Collectively, these results established 
that the R576 substitution selectively augmented some IL-4R–
dependent responses in T and B cells and in BMDMs but   
not others.
The R576 substitution does not augment proximal  
STAT6 activation
To elucidate signaling mechanisms by which the R576 sub-
stitution mediates its proallergic inflammatory effects, we ex-
amined the capacity of the R576 mutation to augment the 
activation of STAT6 in different cell types in response to   
IL-4 and IL-13. Results revealed that the R576 substitution 
did not augment the increase in STAT6 phosphorylation in 
response to IL-4 in T or B cells, nor did it alter the time 
course of STAT6 dephosphorylation in both cell types upon 
the cessation of IL-4 treatment (Fig. 7, A–C). Because T and 
B cells express the type I but not type II IL-4R and, as such, 
do not respond to IL-13, we examined STAT6 activation in 
response to IL-4 and IL-13 in BMDMs, which express both 
the type I and II IL-4Rs. There were no differences in the 
induction of STAT6 phosphorylation, or in its dephosphory-
lation upon signal termination, between WT and R576 
mutant BMDMs treated with IL-4 or IL-13 (Fig. 7, D–F and 
G–I, respectively). These results established that the R576 
substitution did not directly affect STAT6 activation in T and 
B lymphocytes or BMDMs.
We also examined the activation of several pathways 
downstream of IL-4R that have been previously implicated 
in receptor signaling. The R576 substitution was not associ-
ated with enhanced Shc phosphorylation, nor was it associ-
ated with enhanced activation of the PI3-kinase–Akt pathway, 
suggesting that the association at the I4R motif and the sub-
sequent activation of the adaptor IRS2, which lies upstream 
of PI3-kinase–Akt, was similarly unperturbed (Fig. S3).
To further determine the role of STAT6 in the up-regula-
tion of allergic airway inflammation in the R576 mutant   
mice, we examined the induction of goblet cell metaplasia and   
tissue eosinophilia in doxycycline-treated WT and mutant 
mice that harbor the CC10-driven IL-13tg and are either 
STAT6 sufficient or deficient. Goblet cells and eosinophils 
were  detected  by  tissue  staining  with  anti-MUC5AC  and 
anti-eosinophil major basic protein 1 (MBP1) antibodies, re-
spectively. Results revealed that although doxycycline-/ 
IL-13tg–induced goblet cell metaplasia was increased in the 
R576 mutant mice as compared with the Q576 control mice, 
concurrent STAT6 deficiency abrogated goblet cell metapla-
sia in both mouse strains (Fig. 8, A and B). STAT6 deficiency 
reduced tissue eosinophilia induced by doxycylcine/IL-13tg 
substitution did not affect the up-regulation by IL-4 of CD23 
and the MHC class II antigen expression in B cells, which 
proceeds in a STAT-6–dependent manner (Fig. 6 D; Kaplan 
et al., 1996; Shimoda et al., 1996).
Figure 6.  The R576 substitution enhances IL-4 production by 
Th2 cells and IgE responses in vivo. (A) Cytokine production by Th 
cells. Naive WT and R576 splenic T cells (n = 12 mice per group) were 
differentiated into Th1 or Th2 cells, and stimulated with anti-TCR mAB 
for 48 h. Culture supernatants were examined for IL-4 and IFN- pro-
duction by ELISA. (B) Total and OVA-specific serum IgE levels in Q576R 
and WT control mice (n = 13 per group) after i.p. immunization with 
OVA/alum. Horizontal bars represent means. (C) IgE and IgG1 production 
by purified splenic B cells of Q576R and WT control mice (n = 6 per 
group) stimulated in vitro for 1 wk with anti-CD40 mAb+ increasing 
concentrations of IL-4. (D) Up-regulation of CD23 and I-Ad expression in 
WT and R576 B cells treated with increasing concentrations of IL-4 (n = 
3 per group). Values represent means ± SEM derived from two to four 
independent experiments. MFI, mean fluorescence intensity. **, P < 0.01; 
***, P < 0.001; and †, P < 0.05 by repeat measures two-way ANOVA.2198 IL4RA ALLELES IN ASTHMA PATHOGENESIS | Tachdjian et al.
of IL-4R that have been previously implicated in receptor 
signaling. Induction of IL-13tg expression by doxycycline 
treatment was associated with enhanced MAPK phosphory-
lation in lung extracts of B6.129Il4raR576/R576/IL-13tg mice 
as compared with similarly treated B6.129.Il4raR576/R576/ 
IL-13tg controls (Fig. S3 A). Similarly, treatment of primary 
cultures of tracheal airway epithelial cells (TECs) revealed 
that IL-4 treatment of C.129.Il4raR576/R576 cells was associ-
ated with enhanced Erk1/2 kinase activation (Fig. S3 B). IL-4 
(and IL-13) treatment of C.129.Il4raR576/R576 TEC cultures 
was not associated with enhanced Shc phosphorylation, sug-
gesting that the enhancement of MAPK activation proceeded 
by a distinct mechanism (Fig. S3 B and not depicted). Treat-
ment of TEC cultures with IL-4 resulted in increased expres-
sion of Ccl11 transcripts, with a twofold superinduction noted 
in  mutant  C.129.Il4raR576/R576  TECs  as  compared  with 
C.129.Il4raQ576/Q576 controls. This differential induction of 
Ccl11 transcripts in mutant TEC cells was sensitive to inhibi-
tion by the MAPK inhibitor PD98059 (Fig. S3 C). Activa-
tion of other downstream kinases, including AKT and p38 
back to background levels in Q576 control mice. In contrast, 
the STAT6-deficient R576 mutant mice continued to ex-
hibit significantly increased eosinophil infiltration, reaching 
up to 50% of that observed in STAT6-sufficient R576 mutant 
mice (Fig. 8, C and D). The residual, STAT6-independent 
tissue eosinophilia in the triple-transgenic B6.Il4raR576/R576/
STAT6//IL-13tg+ mice involved a Ccl11- and Alox15-
  independent mechanism, as the increased Ccl11 and Alox15 
expression induced by the IL-13tg was abolished in both WT 
and mutant mice by concurrent STAT6 deficiency (Fig. 8, 
E and F). Hence, although the R576 mutation augmented 
several STAT6-dependent responses, the promotion by R576 
allele of tissue eosinophilia involved both STAT6-dependent 
and -independent mechanisms.
Activation of alternative signaling pathways  
by the R576 substitution
To determine potential alternative mechanisms by which the 
R576 substitution promoted allergic airway inflammation, 
we examined the activation of other pathways downstream 
Figure 7.  The R576 substitution does not affect STAT6 activation by IL-4 or IL-13. (A) Intracellular staining of pSTAT6 in WT (Q576) and mutant 
R576 B cells stimulated for 15 min at 37°C with 10 ng/ml IL-4. (B and C) Flow cytometric analysis of pSTAT6 induction in WT and mutant R576 B cells (B) 
or T cells (C) treated with increasing concentrations of IL-4. (D–I) Flow cytometric analysis of pSTAT6 induction in BMDMs. (D and G) Intracellular staining 
of pSTAT6 in BMDMs treated with IL-4 (D) or IL-13 (G). (E and H) pSTAT6 induction at increasing concentrations of IL-4 (E) or IL-13 (H). (F and I) Decay of 
pSTAT6 signal upon cessation of IL-4 and IL-13 treatment. Cells were treated for 10 min with 10 ng/ml IL-4 or 100 ng/ml IL-13, and washed (arrow) and 
analyzed at different time points thereafter for pSTAT6 content. Results represent means ± SEM of lymphocytes, and BMDM cultures from three to five 
mice per group from two to three independent experiments. MFI, mean fluorescence intensity.JEM VOL. 206, September 28, 2009 
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disease susceptibility and modifier loci. In addition, the poly-
morphisms under study might be but markers in linkage dis-
equilibrium with other true disease susceptibility loci. Finally, 
any particular polymorphism may influence only selective as-
pects of a complex phenotype such as asthma. In the present 
study, we have addressed some of these restrictions as they 
apply to the IL-4R Q576R polymorphism by studying the 
functional impact of this polymorphism in the context of the 
mouse receptor, in which the Q576 residue and the motif 
within which it is embedded are conserved. By comparing 
the functional attributes of the WT and the R576 mutant 
MAPK, appeared unaffected by the R576 substitution (un-
published data). Collectively, these findings identified en-
hanced MAPK activation as one putative effector mechanism 
of the IL-4R R576 substitution.
DISCUSSION
Several factors restrict the interpretation of association studies 
examining the role of genetic polymorphisms in the patho-
genesis of allergic diseases, including asthma. These include 
the  genetic  heterogeneity  of  outbred  human  populations, 
which results in confounding genetic influences from other 
Figure 8.  STAT6-dependent and -independent effects of the R576 substitution. (A and B) Induction of MUC5AC expression in airway epithelial 
cells. (A) IL-13tg+ B6.Il4raQ576/Q576 and B6.129Il4raR576/R576 mice, and tg-negative controls, that were either STAT6 sufficient or deficient were examined by 
immunofluorescence staining for expression of MUC5AC after doxycycline (Dox) treatment (red-staining cells). (B) MUC5AC+ cells (red-staining cells; A) 
were counted and expressed as the percentage of total airway epithelial cells (DAPI [blue]-staining nuclei) in the respective airways. (C and D) Lung tissue 
eosinophilia. (C) Mouse groups as in A were treated with doxycycline, and their lungs were stained with anti-eosinophil MBP1 antibodies (red-staining 
cells). (D) MBP1+ cells were counted and expressed as mean cell numbers per 20× objective field (n = 10 fields per group). (E and F) Real-time PCR analysis 
of Ccl11 and Alox15 expression in the different mouse groups treated with doxycycline. Values represent means ± SEM of 4–15 mice per group derived 
from three to five independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars, 100 µm.2200 IL4RA ALLELES IN ASTHMA PATHOGENESIS | Tachdjian et al.
increased proximal STAT6 activation may be best explained 
by the activation by the R576 substitution of an alternative 
signaling mechanism that acts in synergy with STAT6 in a 
gene- and tissue-specific manner. This conclusion is sup-
ported by the finding that the enhanced eosinophil accumu-
lation in lung tissues of Il4raR576/R576/IL-13tg+ mice proceeds 
in part by STAT6-independent mechanisms (Fig. 8). In-
creased MAPK activation was observed in lung tissues of   
Il4raR576/R576/IL-13tg+ mice and in cultured Il4raR576/R576 
primary TECs, indicating that this may represent one such 
mechanism (Duan et al., 2005; Lee et al., 2006). However, 
the precise mechanisms by which the R576 alter signaling 
via the IL-4R, and the role of MAPK and other signaling 
pathways in mediating the effects of the R576 substitution, 
remains to be fully established.
Earlier studies have linked the R576 substitution to   
altered binding at Y575 with increased association with SHP-1 
and SHP-2 (Hershey et al., 1997; Kruse et al., 2002). More 
detailed analysis revealed that recombinant SHP-1 protein 
selectively binds to the ITIM at positions Y713 and Y709 in 
the human and mouse receptors, respectively. Mutagenesis of 
the  ITIM  in  vivo  was  associated  with  enhanced  STAT6 
phosphorylation, grossly elevated baseline serum IgE levels, 
and exaggerated total and antigen-specific IgE responses upon 
antigen sensitization (unpublished data). These findings indi-
cated that the effects of the R576 substitution are distinct 
from those associated with disruption of a bona fide ITIM.
Epidemiological  surveys  have  linked  different  IL-4R 
polymorphisms to distinct phenotypes of atopy and asthma. 
In particular, the R576 allele has been linked to severe asthma 
and low lung function in asthmatics. Other alleles such as the 
cysteine 431 arginine (C431R) have been linked to atopy, 
whereas the E400A has been linked to both severe asthma 
and atopy (Ober et al., 2000; Wenzel et al., 2007). Further-
more, the linkage to both asthma and atopy appears to be 
strengthened  when  analysis  involves  combinatorial  haplo-
types of different IL-4R polymorphisms, indicative of in-
teraction among the alleles (Ober et al., 2000; Risma et al., 
2002; Hytönen et al., 2004). These findings are consistent 
with some of the IL-4R polymorphisms acting by distinct 
though possibly overlapping mechanisms to promote atopy 
and asthma. It would be important to decipher the molecular 
mechanisms underlying these interactions, as they are likely 
to reflect on the different clinical phenotypes associated with 
asthma, including disease progression and severity.
Previous analysis has indicated that the association of the 
R576 polymorphism with severe asthma is independent of 
the racial group analyzed (Wenzel et al., 2007). However, the 
R576 polymorphism exists at a much higher prevalence among 
individuals of African and African-American descent, groups 
that suffer disproportionately from complications of asthma 
(Caggana et al., 1999; Ober et al., 2000; Wu et al., 2001; 
Mannino et al., 2002; Akinbami and Schoendorf, 2002). Al-
though some of the disparity could be attributed to environ-
mental and social factors, a substantial genetic contribution 
exists (Barnes et al., 2007). Furthermore, ethnicity-specific 
alleles on a homogenous genetic background, we have iden-
tified a role for this polymorphism in promoting atopic re-
sponses and allergic airway inflammation and remodeling.
The R576 allele potentiated allergic airway inflammation 
in an antigen-dependent (OVA sensitization) and -independent 
manner (IL-13 inhalation and transgenic expression). In both 
cases, the inflammation was associated with increased airway 
eosinophilia, which persisted in the chronic antigen-driven 
airway inflammation model. Given that airway eosinophilia 
plays a critical role in unfolding the acute and chronic changes 
associated with asthma, including AHR, mucous production, 
and  subepithelial  fibrosis,  the  increased  airway  eosinophil 
load would provide one mechanism by which the R576   
allele promotes allergic airway inflammation (Humbles et al., 
2004; Lee et al., 2004). Gene expression profiling identified 
additional mechanisms by which the R576 allele may exert 
proinflammatory functions. A subset of IL-13–regulated 
genes associated with airway inflammation, remodeling, and 
mucus production, including Alox15, Retnlb, Clca3, and oth-
ers were superinduced by the R576 allele. Although some 
metabolites of 15-lipoxygenase, such as the lipoxins, may 
serve an antiinflammatory function, others such as 15(S)-
  hydroxyeicosatetraenoic acid may promote airway remodeling 
(Chu et al., 2002; Kühn and O’Donnell, 2006). In addition, 
expression of Clca3 is sufficient for induction of goblet cell 
metaplasia in mice (Patel et al., 2006). Collectively with the 
recent demonstration of the induction of subepithelial fibro-
sis by resistin-like , these findings point to potential targets 
of intervention to interrupt the evolution of chronic airway 
changes promoted by the R576 allele (Mishra et al., 2007).
The R576 allele enhanced total and antigen-specific IgE 
responses, a likely reflection of both increased IL-4 produc-
tion by Th2 cells and IL-4–driven isotype switching to  
heavy chain in B cells. An increased atopic response and a 
heightened resident airway tissue response to IL-4 and IL-13 
may both contribute to the aggressive allergic airway inflam-
matory phenotype of the R576 allele. However, the capacity 
of the R576 allele to potentiate IL-13–induced allergic air-
way inflammation, which proceeds in the absence of an IgE-
associated adaptive immune response, indicates that the 
airway inflammatory phenotype can be uncoupled from the 
atopic response. Nevertheless, it is likely that the two mecha-
nisms interact synergistically in vivo in the context of an   
antigen-driven allergic airway inflammation.
The  proallergic  inflammatory  phenotype  of  the  R576   
allele was associated with the selective enhancement of some 
STAT6-dependent responses in a tissue- and gene-specific 
manner but in the absence of increased STAT6 phosphoryla-
tion on the regulatory tyrosine residue or the activation of 
pathways such as PI3-kinase–Akt, Shc, or p38 MAPK. These 
findings are in agreement with an earlier report that failed to 
document evidence of enhanced STAT6 activation in mouse 
cell lines transfected with a human IL-4R allele carrying the 
R576 substitution (Wang et al., 1999).
The capacity of the R576 substitution to selectively aug-
ment some STAT6-dependent responses in the absence of JEM VOL. 206, September 28, 2009 
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LoxP-containing allele: F, 5-GGTGTCTATTTTAGGTGCC-3, and   
R, 5-TCTTCTCTCTTACTCTGTGCT-3. For RT-PCR analysis, total   
RNA  was  extracted  from  splenocytes  of  WT  and  IL-4R  Q576R 
mutant mice using TRIzol (Invitrogen). The RNA was treated with   
Dnase I to remove residual genomic DNA contamination and reverse   
transcribed. Il4ra transcripts were amplified by a two-step process using   
the following pairs of nested primers: outer pair F (exon 11), 5-CAG-
ACCCGAAGCCAGGAGTCAACC-3,  and  R,  (exon  12)  5-CCCT-
GCTTCACTGCCTGCACAAAC-3; and inner pair (both exon 12) F,   
5-GAGCAGCCTTCACACCAG-3,  and  R,  5-ACTGCCTGCACAA-
ACTCCT-3. For GAPDH transcripts, the following primers were used: F, 
5-ACCACAGTCCATGCCATCAC-3, and R, 5-TCCACCACCCT-
GTTGCTGTA-3. For real-time PCR analysis, cDNA was reverse tran-
scribed from 2 µg RNA per sample and used in real-time PCR assays 
that used commercially available oligonucleotides and SYBR green–based 
reagents (SABiosciences). The comparative Ct (threshold cycle) method 
normalized to GAPDH was used to analyze relative changes in gene ex-
pression. The fold change was calculated as 2Ct for negative Ct 
values (indicating a fold-change increase) and 2Ct for positive Ct 
values (indicating a fold-change decrease).
Serum total and OVA-specific IgE antibodies, in vitro IgE production, 
and Th cell differentiation. These assays were performed as previously   
described (Blaeser et al., 2003).
Cell preparation, stimulation, and immunoblotting. Purified T and 
B cell populations were derived by magnetic bead separation (Blaeser et al., 
2000). BMDMs, primary lung fibroblast cultures, and primary air–liquid 
interface cultures of mTECs were established as previously described (You 
et al., 2002; Sugiura et al., 2007). Cells were serum starved for 4 h (T and 
B cells) or overnight (BMDMs, fibroblasts, and mTECs) at 37°C before 
stimulation with IL-4 or IL-13 at the concentrations and time periods   
indicated in the figures. Immunoblotting was performed as previously   
described (Blaeser et al., 2000). The following antibodies were used: anti-
pSTAT6 and -STAT6 (Santa Cruz Biotechnology, Inc.), and anti-pAKT, 
-AKT, -pERK1/2, -ERK1/2, -p38, and -p38 (Cell Signaling Technol-
ogy). The blots were developed using horseradish peroxidase–conjugated 
secondary antibodies and enzyme-linked chemiluminescence (ECL; GE 
Healthcare).
Flow  cytometry  and  intracellular  staining.  Single-cell  suspensions 
were stained with the antibodies indicated in the figures and analyzed on a 
cytometer (FACSCalibur; BD). FITC- or PE-conjugated mAbs used were 
obtained from BD and eBioscience. Intracellular staining with anti–phospho-
Y641–STAT6 (pSTAT6), anti–phospho–threonine 308–AKT (pAKT), 
and anti–pT180/pY182 p38 MAPK (pp38) antibodies (BD) was performed 
as previously described (Krutzik et al., 2004). Cell aliquots were stimulated 
with IL-4 or IL-13 (PeproTech) for the periods and concentrations indi-
cated in the figures. The cells were then fixed with 1.6% paraformaldehyde 
and permeabilized for 10 min with methanol. After washing, the cells were 
stained with conjugated pSTAT6, pAKT, or pp38 (Alexa Fluor 647; BD) 
and analyzed by flow cytometry.
Immunofluorescence. Tissue section preparation was performed as previ-
ously described (Gomperts et al., 2007). Primary antibodies used were mouse 
anti-Muc5AC mAb (1:100; Neomarkers) and 0.4 µg/ml of monoclonal rat 
anti–mouse eosinophil MBP1 mAb 14.7.4 (a gift of J. Lee; Mayo Clinic   
Arizona, Scottsdale, AZ). Sections were incubated with either Alexa Fluor 568 
goat anti–mouse antibody (for MUC5AC staining) or biotinylated secondary 
antibody for 45 min, and then with Texas red–avidin (for MBP1 staining). 
After washing in PBS, all slices were stained by DAPI (Vector Laboratories) 
for 2 min and mounted. All images were obtained with a fluorescent micro-
scope (Axioskop 2 Plus; Carl Zeiss, Inc.) and a camera (AxioCam HR; Carl 
Zeiss, Inc.), and imaged with a scanner (AxioVision; Carl Zeiss, Inc.) and LE 
Real 4.2 software.
interactions between IL-13 and IL-4R alleles have been 
demonstrated for African Americans with asthma (Battle   
et al., 2007). The specific contribution of the R576 allele to 
asthma incidence and severity among different ethnic groups, 
especially African Americans, requires further investigation. 
Its association with a distinct mechanism of cellular activation 
via the IL-4R suggests, however, that novel therapeutic in-
terventions may be beneficial to asthma treatment in this and 
other ethnic groups.
MATERIALS AND METHODS
Construction of targeting vector and generation of mutant mice. 
Genomic DNA used to construct the targeting vector were isolated from a 
bacterial artificial chromosome clone derived from the 129X1Sv/J mouse 
strain that contained the mouse IL-4R gene (Genome Systems; Wrighton 
et al., 1992). The replacement-type targeting vector (pKO; Lexicon) con-
tained 13.5 kb of IL4RA sequences that extended from a XhoI site proximal 
to exon 9 to a KpnI site distal to exon 12 of the gene. An AG→GA substitu-
tion was introduced by site-directed mutagenesis (QuickChange; Agilent 
Technologies) into the second and third positions of codon Q576 (corre-
sponding to bp 1964–1965 of the mouse IL-4R cDNA; Mosley et al., 
1989), changing it to R576 (CGA). The targeting construct included a floxed 
neomycin resistance gene (neo) and a diphtheria toxin gene for positive/
negative selection. Targeting plasmids were transfected into RW4 ES cells 
and subjected to G418 selection. Successfully targeted clones were transiently 
transfected with a Cre recombinase to remove the inserted neomycin gene.
Heterozygous ES cells were injected into C57BL/6 blastocysts, and the 
resultant male chimeras were mated with BALB/c females. Offspring were 
screened for Hets by Southern blotting and PCR analysis. Heterozygous an-
imals  were  further  bred  for  10  generations  on  BALB/c  (Taconic)  and 
C57BL/6 (Charles River Laboratories) backgrounds to generate the con-
genic strains C.129Il4raR576/R576 and B6.129.Il4raR576/R576. A targeted clone 
in which the floxed neo cassette was incorporated (later removed by Cre re-
combinase action) but which retained the WT Q576 codon was used to 
generate  the  control  C.129.Il4raQ576/Q576  congenic  mouse  strain.  WT 
BALB/c and IL-4R KO mice (BALB/c-Il4ra tm1Sz) were obtained from 
Taconic and the Jackson Laboratory, respectively. All protocols were in ac-
cordance with National Institutes of Health (NIH) guidelines and approved 
by the Animal Care and Use Committee at the University of California, Los 
Angeles. The C.129Il4raR576/R576 strain has been deposited at the Jackson 
Laboratory (strain no. 007746).
Control  and  IL-13tg  strains. The mouse Il4ra exists as two distinct   
allotypes, each restricted to different strains of inbred mice, that differ at   
multiple polymorphic residues (Schulte et al., 1997). The 129X1Sv/J and 
C57BL/6 strains share the same allotype targeted by mutagenesis in this 
study, whereas BALB/c mice carry the other. Accordingly, for studies on 
the BALB/c background, the C.129.Il4raQ576/Q576 mice were used as con-
trols except for experiments specifically indicated in the figures in which 
native BALB/c mice were used. For studies on the C57BL/6 background, 
native C57BL/6 mice were used as controls. The doxycycline-inducible 
IL-13tg mice (CC10-rtTA–IL-13, on a C57BL/6 background; designated 
in this study as B6.Il4raQ576/Q576/IL-13tg) were a gift of J. Elias (Yale Uni-
versity School of Medicine, New Haven, CT; Zheng et al., 2000). B6.129.
Il4raR576/R576 mice were backcrossed on the IL-13tg mice to create the 
B6.129.Il4raR576/R576/IL-13tg strain.
PCR analysis. Screening of WT and mutant Il4ra alleles was performed 
by PCR amplification using genomic DNA and the following primers: 
common  forward  (F)  primer,  5-TTGCAGACAATCCTGCCTA-3;   
WT-specific reverse (R) primer, 5-ACTGCCTGCACAAACTCCT-3;   
and mutant-specific R primer, 5-ACTGCCTGCACAAACTCTC-3.   
The  following  primers  were  used  for  PCR  screening  of  the  residual 2202 IL4RA ALLELES IN ASTHMA PATHOGENESIS | Tachdjian et al.
Il4raR576/R576 mice are detailed in Tables S1–S5. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20091480/DC1.
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